Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
A Multi-Center, Randomized, Double-Masked Parallel Group Study Evaluating the Efficacy, Safety, and QOL of R89674 0.25% Ophthalmic Solution Compared to Vehicle or an Active Control in a Modified Model of Environmental Seasonal Allergic Conjunctivitis
Sponsor: Vistakon Pharmaceuticals
Listed as NCT00364091, this PHASE3 trial focuses on Allergic Conjunctivitis and remains completed. Sponsored by Vistakon Pharmaceuticals, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vistakon Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Charlotte, United States
- • Creve Coeur, United States
- • Louisville, United States
- • Memphis, United States
- • North Andover, United States
- • Philadelphia, United States